Serena Williams is opening up about her fitness journey, revealing that she uses the injectable GLP-1 weight loss drug ...

With 23 Grand Slam singles titles and four Olympic gold medals, Serena Williams is undeniably a superathlete. But the 43-year ...

Serena Williams recently detailed her weight loss journey, sharing that she lost 31 pounds with the assistance of a GLP-1 ...

Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

Tricare officials said the Defense Health Agency is eliminating coverage for its Tricare for Life beneficiaries and others to ...

Studies have found that semaglutide, the chemical in Ozempic, reduced alcohol intake, binge drinking and relapse ...

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Serena Williams reveals her use of GLP-1, Zepbound and calls out the stigma surrounding the use of the popular weight loss drug.

For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and those who were overweight versus obese.< Patients taking GLP-1 agonists for ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.